Cohance Lifesciences Limited
1,306words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
43.28%
MFY21 9MFY22 9MFY21 9MFY22 Note:Figures in Rs. Crore 6 Financial Snapshot Growth in Revenue 43.28% Growth in EBITDA Growth in PAT 37.37% 40.31% 32.60% 32.99% 36.63% Q3FY22 9MFY22 7 Key Ra
37.37%
es in Rs. Crore 6 Financial Snapshot Growth in Revenue 43.28% Growth in EBITDA Growth in PAT 37.37% 40.31% 32.60% 32.99% 36.63% Q3FY22 9MFY22 7 Key Ratios Growth in EBIT 38.51% EBITDA to
40.31%
. Crore 6 Financial Snapshot Growth in Revenue 43.28% Growth in EBITDA Growth in PAT 37.37% 40.31% 32.60% 32.99% 36.63% Q3FY22 9MFY22 7 Key Ratios Growth in EBIT 38.51% EBITDA to Income
32.60%
6 Financial Snapshot Growth in Revenue 43.28% Growth in EBITDA Growth in PAT 37.37% 40.31% 32.60% 32.99% 36.63% Q3FY22 9MFY22 7 Key Ratios Growth in EBIT 38.51% EBITDA to Income PAT to
32.99%
ncial Snapshot Growth in Revenue 43.28% Growth in EBITDA Growth in PAT 37.37% 40.31% 32.60% 32.99% 36.63% Q3FY22 9MFY22 7 Key Ratios Growth in EBIT 38.51% EBITDA to Income PAT to Income
36.63%
apshot Growth in Revenue 43.28% Growth in EBITDA Growth in PAT 37.37% 40.31% 32.60% 32.99% 36.63% Q3FY22 9MFY22 7 Key Ratios Growth in EBIT 38.51% EBITDA to Income PAT to Income 48.72%
38.51%
owth in PAT 37.37% 40.31% 32.60% 32.99% 36.63% Q3FY22 9MFY22 7 Key Ratios Growth in EBIT 38.51% EBITDA to Income PAT to Income 48.72% 34.18% 33.69% 50.82% 33.04% Q3FY22 9MFY22 8 Fina
48.72%
36.63% Q3FY22 9MFY22 7 Key Ratios Growth in EBIT 38.51% EBITDA to Income PAT to Income 48.72% 34.18% 33.69% 50.82% 33.04% Q3FY22 9MFY22 8 Financials Q3FY22 Revenue EBIDTA 4,009 1,95
34.18%
Q3FY22 9MFY22 7 Key Ratios Growth in EBIT 38.51% EBITDA to Income PAT to Income 48.72% 34.18% 33.69% 50.82% 33.04% Q3FY22 9MFY22 8 Financials Q3FY22 Revenue EBIDTA 4,009 1,953 3,393
33.69%
9MFY22 7 Key Ratios Growth in EBIT 38.51% EBITDA to Income PAT to Income 48.72% 34.18% 33.69% 50.82% 33.04% Q3FY22 9MFY22 8 Financials Q3FY22 Revenue EBIDTA 4,009 1,953 3,393 2,798
50.82%
7 Key Ratios Growth in EBIT 38.51% EBITDA to Income PAT to Income 48.72% 34.18% 33.69% 50.82% 33.04% Q3FY22 9MFY22 8 Financials Q3FY22 Revenue EBIDTA 4,009 1,953 3,393 2,798 1,601
33.04%
Ratios Growth in EBIT 38.51% EBITDA to Income PAT to Income 48.72% 34.18% 33.69% 50.82% 33.04% Q3FY22 9MFY22 8 Financials Q3FY22 Revenue EBIDTA 4,009 1,953 3,393 2,798 1,601 1,422 N
Advertisement